Comment from Kanesha Jones

Summary: Kanesha Jones, an MPH candidate at Yale School of Public Health, submits a comment regarding the FDA's proposal to exclude certain drugs from the 503B Bulks List. While she does not dispute the agency's clinical-need findings, she urges the FDA to acknowledge the potential for "access harm" among vulnerable populations and recommends a commitment to monitor these population-level consequences.